Evaluation of linear versus star-like polymer anti-cancer nanomedicines in mouse models

J Control Release. 2023 Jan:353:549-562. doi: 10.1016/j.jconrel.2022.11.060. Epub 2022 Dec 10.

Abstract

Nanomedicines are considered next generation therapeutics with advanced therapeutic properties and reduced side effects. Herein, we introduce tailored linear and star-like water-soluble nanosystems as stimuli-sensitive nanomedicines for the treatment of solid tumors or hematological malignancies. The polymer carrier and drug pharmacokinetics were independently evaluated to elucidate the relationship between the nanosystem structure and its distribution in the body. Positron emission tomography and optical imaging demonstrated enhanced tumor accumulation of the polymer carriers in 4T1-bearing mice with increased tumor-to-blood and tumor-to-muscle ratios. Additionally, there was a significant accumulation of doxorubicin bound to various polymer carriers in EL4 tumors, as well as excellent in vivo therapeutic activity in EL4 lymphoma and moderate efficacy in 4T1 breast carcinoma. The linear nanomedicine showed at least comparable pharmacologic properties to the star-like nanomedicines regarding doxorubicin transport. Therefore, if multiple parameters are considered such as its optimized structure and simple and reproducible synthesis, this polymer carrier system is the most promising for further preclinical and clinical investigations.

Keywords: Biodistribution; Cancer; Drug delivery; HPMA; Polymeric carriers; Positron emission tomography.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Disease Models, Animal
  • Doxorubicin / pharmacokinetics
  • Drug Carriers* / chemistry
  • Mice
  • Nanomedicine
  • Polymers* / chemistry

Substances

  • Polymers
  • Drug Carriers
  • Doxorubicin